Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the American ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback